Last edition
News about "Overall Survival "
Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer
Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
Overall Survival | 19/05/2026 | By News Bureau
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Overall Survival | 15/05/2026 | By News Bureau
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Overall Survival | 15/11/2025 | By Dineshwori | 310
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy